Boehringer Ingelheim expands animal health portfolio in India market with two new drugs launches Read more
Cipla continues to expand focus on therapy areas of promising growth through deals: GlobalData Read more
Linagliptin demonstrates cardiovascular and renal safety in Asian adults with type 2 diabetes Read more
DCGI approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease Read more
Boehringer Ingelheim and CDR-Life to develop Antibody Fragment-based Therapeutics for Geographic Atrophy Read more
Giving highest priority to ensure uninterrupted supply of medicines: Sharad Tyagi, Boehringer Ingelheim, India Read more